This exhaustive study covering tumor recurrence in genetically engineered mouse models, human breast cancer cell lines, and gene expression profile of 2200 breast cancer patients of all subtypes and clinicopathological characteristics showed a clear correlation of high CERK expression with aggressive tumors and poor clinical outcome following adjuvant or neoadjuvant therapy. This evidence concerns the gene CERK and breast carcinoma.